<DOC>
	<DOCNO>NCT01438814</DOCNO>
	<brief_summary>The aim study investigate impact combination therapy linagliptin metformin submaximal dos reduction Glycosylated haemoglobin ( HbA1c ) metformin pre-specified gastro-intestinal ( GI ) side effect treatment naive patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Linagliptin Combination With Metformin Treatment Naive Patients With Type 2 Diabetes Mellitus Insufficient Glycaemic Control</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis Type 2 diabetes mellitus ( T2DM ) prior inform consent ; 2 . Male female patient diet exercise regimen drug naive , define absence oral antidiabetic therapy insulin 12 week prior randomization 3 . Glycosylated haemoglobin A1c ( HbA1c ) &gt; /= 7.0 % ( 53 mmol/mol ) &lt; /= 10.0 % ( 86 mmol/mol ) visit 1 ( screen ) ; 4 . Age &gt; /=18 &lt; /=80 year visit 1 ( screen ) ; 5 . Body Mass Index ( BMI ) &lt; /= 45kg/m2 visit 1 ( screen ) ; 6 . Signed date write informed consent date visit 1 accordance Good Clinical Practice ( GCP ) local legislation Exclusion criterion : 1 . Uncontrolled hyperglycaemia glucose level &gt; 240 mg/dl ( 13.3mmol/L ) overnight fast screening/placebo runin confirm second measurement ( Not day ) ; 2 . Treatment oral antidiabetic drug insulin within 12 week prior randomization 3 . Acute coronary syndrome ( nonSTEMI , STEMI unstable angina pectoris ) , stroke Transient ischemia attack ( TIA ) within 3 month prior inform consent ; 4 . Indication liver disease/Impaired hepatic function , define serum level either Aspartate aminotransferase ( ALT SGPT ) , alanine aminotransferase ( AST SGOT ) , alkaline phosphatase 3 x upper limit normal ( ULN ) determine visit 1 and/or runin phase , 5 . Impaired renal function , define eGFR &lt; 60ml/min ( moderate severe renal impairment , modification diet renal disease ( MDRD ) formula ) determine screen runin phase 6 . Bariatric surgery within past two year gastrointestinal surgery induce chronic malabsorption 7 . Medical history Cancer ( except basal cell carcinoma ) and/or treatment cancer within last 5 year 8 . Blood dyscrasia disorder cause haemolysis unstable Red Blood Cell ( eg . malaria , babesiosis , haemolytic anemia ) 9 . Known history pancreatitis chronic pancreatitis 10 . Contraindications metformin accord local label 11 . Treatment antiobesity drug 3 month prior inform consent treatment time screen ( i.e . surgery , aggressive diet regimen etc ) lead unstable body weight 12 . Current treatment systemic steroid time informed consent change dosage thyroid hormone within 6 week prior inform consent uncontrolled endocrine disorder except T2DM 13 . Premenopausal woman ( last menstruation less 1 year prior informed consent ) : 1. nursing pregnant 2. childbearing potential practicing acceptable method birth control , plan continue use method throughout study agree submit periodic pregnancy test participation trial agree continue contraception least 30 day last dose study drug . Acceptable method birth control include tubal ligation , transdermal patch , intrauterine devices/systems ( IUDs/IUSs ) , oral , implantable , injectable contraceptive , complete sexual abstinence ( acceptable local authority ) , double barrier method vasectomize partner . 14 . Alcohol drug abuse within 3 month prior inform consent would interfere trial participation ongoing condition lead decrease compliance study procedure study drug intake 15 . Participation another trial application investigational drug within 30 day prior inform consent 16 . Any clinical condition would jeopardize patient safety participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>